Effect of ibrutinib on BP over the 60-month study period. (A) Change in mean BP. Error bars represent SD. The cumulative incidence of new (B) or worsened (C) HTN across time after initiation of ibrutinib therapy is also shown. (B) Time to 50% cumulative incidence, 4.2 months; median follow-up, 31.0 months. (C) Time to 40% cumulative incidence, 1.1 months; median follow-up, 29.3 months.